Cantor Fitzgerald analyst Charles Duncan downgraded Vanda Pharmaceuticals to Neutral from Overweight and lowered his price target for the shares to $30 from $38. The company's complaint against the FDA reduces visibility on development timelines for tradipitant in gastroparesis, perhaps even pruritus, and may also affect Hetlioz label expansion efforts, Duncan tells investors in a research note. The "challenged" FDA interactions are a result of management disagreement with the agency over the scientific merits of conducting certain nonclinical testing, says the analyst.